[Michael DeVries]

Who would You Recommend as the Best (= Most Profitable, Most Cost Effective, Highest Return On Investment (ROI)) Stock Picker Subscription Service?

Please Share Your Recommendations for the Best / Highest ROI Stock Picker Subscription Services and Why you say so / recommend them, herein, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/28/2017 – 09/01/2017:

1) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.36
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

2) ONCS – OncoSec Medical Inc
a. Buy at < ~ $0.88
b. Sell at >~ $1.30
c. Catalysts:
1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
2. Q4 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20171011; 20171011; https://www.google.com/finance?q=ONCS
3. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

3) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.10
b. Sell at >~ $1.38

4) TRIL – Trillium Therapeutics Inc.
a. Buy at < ~ $4.15
b. Sell at >~ $4.95
c. Catalysts:
1. Phase 2 – Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer; 20170930; 20170930; https://ClinicalTrials.gov/show/NCT01010126
2. NA – A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting; 20170815; 20181030; https://ClinicalTrials.gov/show/NCT02364531
3. Phase 3 – Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT00324805
4. Phase 3 – Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial); 20171231; 20171231; https://ClinicalTrials.gov/show/NCT00310180
5. Phase 1Phase 2 – Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis–Pilot Trial; 20170601; 20170831; https://ClinicalTrials.gov/show/NCT02334007
6. Phase 3 – Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer; 20140601; 20200630; https://ClinicalTrials.gov/show/NCT00066703
7. Phase 3 – A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer; 20110513; 20220312; https://ClinicalTrials.gov/show/NCT00567190
8. Phase 4 – Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes; 20170501; 20171031; https://ClinicalTrials.gov/show/NCT01351857
9. Phase 3 – Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer; 20150201; 20171231; https://ClinicalTrials.gov/show/NCT00265850
10. Phase 3 – Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT00463489
11. Phase 3 – A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer; 20200101; 20200731; https://ClinicalTrials.gov/show/NCT01101438
12. NA – Womens Initiative Supporting Health Increasing Healthcare Access; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT02964845
13. Phase 3 – Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer; 20220201; 20220228; https://ClinicalTrials.gov/show/NCT01272037
14. Phase 3 – High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery; 20200601; 20200601; https://ClinicalTrials.gov/show/NCT02506153
15. Phase 1 – A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02663518
16. Phase 1 – Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides; 20181201; 20191231; https://ClinicalTrials.gov/show/NCT02890368
17. Phase 3 – Effect of MD1003 in Progressive Multiple Sclerosis (SPI2); 20180901; 20190930; https://ClinicalTrials.gov/show/NCT02936037
18. Phase 3 – Field Randomization of NA-1 Therapy in Early Responders; 20190301; 20190531; https://ClinicalTrials.gov/show/NCT02315443
19. Phase 3 – FIBrinogen REplenishment in Surgery; 20190130; 20190330; https://ClinicalTrials.gov/show/NCT03037424

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/28/2017 – 09/01/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 08/18/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Book/sh = $3.00
4. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
5. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.73
6. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
7. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.19
8. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $22.22
9. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
10. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 08/18/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $ANTH – Anthera Pharmaceuticals Inc :
   1. Cash/sh = $1.97
3. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.95
4. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Cash/sh = $1.93
5. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
6. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
7. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.85
8. $EGLT – Egalet Corp :
   1. Cash/sh = $2.30
9. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.44
10. $ROKA – Roka Bioscience Inc :
    1. Cash/sh = $3.19
11. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Cash/sh = $3.04

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/14/2017 – 08/18/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $5.80

2) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.36
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

3) ONCS – OncoSec Medical Inc
a. Buy at < ~ $0.88
b. Sell at >~ $1.30
c. Catalysts:
1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
2. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

4) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.81
b. Sell at >~ $4.00

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.52
b. Sell at >~ $2.00
c. Catalysts:
1. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/14/2017 – 08/18/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 08/04/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Book/sh = $3.00
4. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
5. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 08/04/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $ANTH – Anthera Pharmaceuticals Inc :
   1. Cash/sh = $1.97
3. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
4. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Cash/sh = $1.93
5. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
6. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
7. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
8. $EGLT – Egalet Corp :
   1. Cash/sh = $2.30
9. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
10. $ROKA – Roka Bioscience Inc :
    1. Cash/sh = $3.19
11. $TNDM – Tandem Diabetes Care Inc :
    1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/07/2017 – 08/11/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $5.80

2) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.40
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

3) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following – i.e. likely 1Q 2018. – NeuVax in combination with Herceptin – Breast cancer – Phase 2b; 20180331; 20180331; https://investors.galenabiopharma.com/investors/press-releases/press-release-details/2017/Galena-Biopharma-Provides-Corporate-Update/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1
5. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
6. Phase 2 – Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02297698
7. Phase 2 – Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax; 20190601; 20200630; https://ClinicalTrials.gov/show/NCT01570036

4) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
a. Buy at < ~ $4.50
b. Sell at >~ $6.05
c. Catalysts:
1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

5) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $3.11
b. Sell at >~ $4.00

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/07/2017 – 08/11/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 07/28/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
5. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.81
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 07/28/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
7. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $3.19
8. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/31/2017 – 08/04/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $5.80

2) CYCC – Cyclacel Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.71
b. Sell at >~ $3.00
c. Catalysts:
1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
3. Phase 2 – Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; 20170801; 20171031; https://ClinicalTrials.gov/show/NCT02649751
4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460
6. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

3) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.32
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

4) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following – i.e. likely 1Q 2018. – NeuVax in combination with Herceptin – Breast cancer – Phase 2b; 20180331; 20180331; https://investors.galenabiopharma.com/investors/press-releases/press-release-details/2017/Galena-Biopharma-Provides-Corporate-Update/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1
5. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
6. Phase 2 – Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02297698
7. Phase 2 – Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax; 20190601; 20200630; https://ClinicalTrials.gov/show/NCT01570036

5) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.38
b. Sell at >~ $2.05
c. Catalysts:
1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

6) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

7) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
a. Buy at < ~ $4.60
b. Sell at >~ $6.05
c. Catalysts:
1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

8) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $3.26
b. Sell at >~ $4.00

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/31/2017 – 08/04/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 07/21/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
5. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.81
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 07/21/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
7. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $3.19
9. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/24/2017 – 07/28/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.62
b. Sell at >~ $5.80

2) CYCC – Cyclacel Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.72
b. Sell at >~ $3.00
c. Catalysts:
1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
3. Phase 2 – Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; 20170801; 20171031; https://ClinicalTrials.gov/show/NCT02649751
4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460
6. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

3) UNXL – Uni-Pixel Inc
a. Buy at < ~ $0.35
b. Sell at >~ $0.60

4) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.32
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

5) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

6) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.47
b. Sell at >~ $2.05
c. Catalysts:
1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

8) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
a. Buy at < ~ $4.60
b. Sell at >~ $6.05
c. Catalysts:
1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/24/2017 – 07/28/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 07/14/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
5. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
6. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.81
7. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 07/14/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
7. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $3.19
9. $TEAR – TearLab Corp :
   1. Cash/sh = $2.20
10. $TNDM – Tandem Diabetes Care Inc :
    1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/17/2017 – 07/21/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.62
b. Sell at >~ $5.80

2) UNXL – Uni-Pixel Inc
a. Buy at < ~ $0.35
b. Sell at >~ $0.60

3) TRIL – Trillium Therapeutics Inc.
a. Buy at < ~ $4.15
b. Sell at >~ $6.90
c. Catalysts:
1. Phase 2 – Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer; 20170930; 20170930; https://ClinicalTrials.gov/show/NCT01010126
2. NA – A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting; 20170815; 20181030; https://ClinicalTrials.gov/show/NCT02364531
3. Phase 3 – Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT00324805
4. Phase 3 – Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial); 20171231; 20171231; https://ClinicalTrials.gov/show/NCT00310180
5. Phase 1Phase 2 – Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis–Pilot Trial; 20170601; 20170831; https://ClinicalTrials.gov/show/NCT02334007
6. Phase 3 – Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer; 20140601; 20200630; https://ClinicalTrials.gov/show/NCT00066703
7. Phase 3 – A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer; 20110513; 20220312; https://ClinicalTrials.gov/show/NCT00567190
8. Phase 4 – Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes; 20170501; 20171031; https://ClinicalTrials.gov/show/NCT01351857
9. Phase 3 – Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer; 20150201; 20171231; https://ClinicalTrials.gov/show/NCT00265850
10. Phase 3 – Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT00463489
11. Phase 3 – A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer; 20200101; 20200731; https://ClinicalTrials.gov/show/NCT01101438
12. NA – Womens Initiative Supporting Health Increasing Healthcare Access; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT02964845
13. Phase 3 – Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer; 20220201; 20220228; https://ClinicalTrials.gov/show/NCT01272037
14. Phase 3 – High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery; 20200601; 20200601; https://ClinicalTrials.gov/show/NCT02506153
15. Phase 1 – A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02663518
16. Phase 1 – Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides; 20181201; 20191231; https://ClinicalTrials.gov/show/NCT02890368
17. Phase 3 – Effect of MD1003 in Progressive Multiple Sclerosis (SPI2); 20180901; 20190930; https://ClinicalTrials.gov/show/NCT02936037
18. Phase 3 – Field Randomization of NA-1 Therapy in Early Responders; 20190301; 20190531; https://ClinicalTrials.gov/show/NCT02315443
19. Phase 3 – FIBrinogen REplenishment in Surgery; 20190130; 20190330; https://ClinicalTrials.gov/show/NCT03037424

4) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.32
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

5) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

6) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.47
b. Sell at >~ $2.05
c. Catalysts:
1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

8) SRRA – Sierra Oncology, Inc.
a. Buy at < ~ $1.10
b. Sell at >~ $1.35
c. Catalysts:
1. Phase 3 – A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130); 20171201; 20181015; https://ClinicalTrials.gov/show/NCT02367781
2. Phase 4 – Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE; 20171201; 20171231; https://ClinicalTrials.gov/show/NCT01491763
3. Phase 3 – A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]; 20180101; 20230215; https://ClinicalTrials.gov/show/NCT02367794
4. N/A – Current Treatment of HCV Infection After HSCT; 20180601; 20180731; https://ClinicalTrials.gov/show/NCT03014986
5. N/A – ClariCoreâ„¢ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02773940
6. N/A – ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02928640
7. Phase 2 – PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine); 20160901; 20180731; https://ClinicalTrials.gov/show/NCT02226965
8. Phase 3 – Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer; 20140401; 20171231; https://ClinicalTrials.gov/show/NCT00288080
9. Phase 3 – A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer; 20170601; 20180630; https://ClinicalTrials.gov/show/NCT01322490
10. Phase 1/Phase 2 – Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation; 20170701; 20180731; https://ClinicalTrials.gov/show/NCT02328885
11. N/A – S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases; 20170701; 20170731; https://ClinicalTrials.gov/show/NCT00874211
12. Phase 2 – Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA); 20180731; 20180731; https://ClinicalTrials.gov/show/NCT02833350
13. Phase 3 – Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT); 20191031; 20191031; https://ClinicalTrials.gov/show/NCT02745119
14. Phase 3 – Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia; 20190901; 20210930; https://ClinicalTrials.gov/show/NCT02785900
15. Phase 3 – A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen; 20220131; 20220131; https://ClinicalTrials.gov/show/NCT02066636
16. N/A – Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms; 20261001; 20261031; https://ClinicalTrials.gov/show/NCT00443274
17. N/A – Connect® MM- The Multiple Myeloma Disease Registry; 20241201; 20241231; https://ClinicalTrials.gov/show/NCT01081028
18. Phase 4 – Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis; 20190808; 20190808; https://ClinicalTrials.gov/show/NCT02092467
19. N/A – Connectâ„¢ CLL: The Chronic Lymphocytic Leukemia Disease Registry; 20190101; 20190131; https://ClinicalTrials.gov/show/NCT01081015
20. Phase 3 – Study Of Diabetic Nephropathy With Atrasentan; 20180731; 20200408; https://ClinicalTrials.gov/show/NCT01858532
21. Phase 1 – A Phase 1 Trial of SRA737 in Subjects With Advanced Cancer; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT02797964
22. Phase 3 – Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02665065
23. Phase 1 – A Phase 1 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02797977

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/17/2017 – 07/21/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/26/2017 – 06/30/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) DGLY – Digital Ally, Inc.
a. Buy at < ~ $3.45
b. Sell at >~ $6.50

3) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.60
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

4) UNXL – Uni-Pixel Inc
a. Buy at < ~ $0.35
b. Sell at >~ $0.60

5) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
4. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
5. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

6) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/26/2017 – 06/30/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/19/2017 – 06/23/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.60
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

3) ROKA – Roka Bioscience Inc – Trading Below Cash
a. Buy at < ~ $2.52
b. Sell at >~ $4.66

4) OVAS – OvaScience Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $2.00
c. Catalysts:
1. @cutterend Mar. 21 at 10:45 PM $OVAS FDA meeting first half of 2017; 20170101; 20170630; http://stocktwits.com/cutterend?utm_campaign=widget&utm_medium=widget&utm_source=finviz.com
2. Q2 2017 OvaScience Inc Earnings Release (Estimated)
-; 20170802; 20170802; https://www.google.com/finance?q=OVAS

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.56
b. Sell at >~ $2.93
c. Catalysts:
1. Q2 – Initiate ph 3 Oral for treatment of refractory invasive fungal infections (rIFI) intolerant to standard antifungal agents (FURI study); 20170401; 20170630; https://twitter.com/crewdog58/status/871138582706180098
2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); expected to start patient enrollment in Q2, 2017; 20170401; 20170630; https://seekingalpha.com/article/4073253-scynexis-another-buy-opportunity-recent-pullback
3. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
4. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3
5. Q2 2017 SCYNEXIS Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=SCYX

6) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

9) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.78
b. Sell at >~ $2.14
c. Catalysts:
1. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/19/2017 – 06/23/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 06/09/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
5. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
6. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
7. $PRTO – Proteon Therapeutics Inc :
   1. Book/sh = $1.98
8. $RXII – RXi Pharmaceuticals Corp :
   1. Book/sh = $1.00
9. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
10. $TOPS – TOP SHIPS Inc :
    1. Book/sh = $196.63

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 06/09/2017 include

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.15
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1
5. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
6. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
7. $PRTO – Proteon Therapeutics Inc :
   1. Cash/sh = $2.56
8. $TCON – TRACON Pharmaceuticals Inc :
   1. Cash/sh = $2.78
9. $TEAR – TearLab Corp :
   1. Cash/sh = $2.77
10. $TNDM – Tandem Diabetes Care Inc :
    1. Cash/sh = $1.06

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/12/2017 – 06/16/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.60
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

3) ROKA – Roka Bioscience Inc – Trading Below Cash
a. Buy at < ~ $2.52
b. Sell at >~ $4.66

4) OVAS – OvaScience Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $2.00
c. Catalysts:
1. @cutterend Mar. 21 at 10:45 PM $OVAS FDA meeting first half of 2017; 20170101; 20170630; http://stocktwits.com/cutterend?utm_campaign=widget&utm_medium=widget&utm_source=finviz.com
2. Q2 2017 OvaScience Inc Earnings Release (Estimated)
-; 20170802; 20170802; https://www.google.com/finance?q=OVAS

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.56
b. Sell at >~ $2.93
c. Catalysts:
1. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); expected to start patient enrollment in Q2, 2017; 20170401; 20170630; https://seekingalpha.com/article/4073253-scynexis-another-buy-opportunity-recent-pullback
2. Q2 – Initiate ph 3 Oral for treatment of refractory invasive fungal infections (rIFI) intolerant to standard antifungal agents (FURI study); 20170401; 20170630; https://twitter.com/crewdog58/status/871138582706180098
3. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
4. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3
5. Q2 2017 SCYNEXIS Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=SCYX

6) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

9) SRNE – Sorrento Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.10
c. Catalysts:
1. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
7. 3 clinical programs in 2017 w/ promising human & in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

10) ONTX – Onconova Therapeutics Inc
a. Buy at < ~ $1.78
b. Sell at >~ $2.14
c. Catalysts:
1. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/12/2017 – 06/16/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 06/02/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
2. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
3. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
4. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
5. $PRTO – Proteon Therapeutics Inc :
   1. Book/sh = $1.98
6. $RXII – RXi Pharmaceuticals Corp :
   1. Book/sh = $1.00
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
8. $TOPS – TOP SHIPS Inc :
   1. Book/sh = $196.63

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 06/02/2017 include

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
2. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.15
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
4. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
5. $PRTO – Proteon Therapeutics Inc :
   1. Cash/sh = $2.56
6. $TCON – TRACON Pharmaceuticals Inc :
   1. Cash/sh = $2.78
7. $TEAR – TearLab Corp :
   1. Cash/sh = $2.77
8. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $1.06

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 06/05/2017 – 06/09/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.77
b. Sell at >~ $5.80

2) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.60
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

3) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.60
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

4) ROKA – Roka Bioscience Inc – Trading Below Cash
a. Buy at < ~ $2.52
b. Sell at >~ $4.66

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.56
b. Sell at >~ $2.93
c. Catalysts:
1. Q2 – Initiate ph 3 Oral for treatment of refractory invasive fungal infections (rIFI) intolerant to standard antifungal agents (FURI study); 20170401; 20170630; https://twitter.com/crewdog58/status/871138582706180098
2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); expected to start patient enrollment in Q2, 2017; 20170401; 20170630; https://seekingalpha.com/article/4073253-scynexis-another-buy-opportunity-recent-pullback
3. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3
4. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912

6) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) ECYT – Endocyte, Inc. – Trading Below Cash
a. Buy at < ~ $1.80
b. Sell at >~ $3.22
c. Catalysts:
1. Phase 1 data for EC1456 and EC1169; 2016; ;
2. Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting; 20170605; 20170605; https://seekingalpha.com/pr/16845518-endocyte-announce-updated-data-ec1456-ec1169-2017-american-society-clinical-oncology-asco

8) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

9) SRNE – Sorrento Therapeutics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $2.10
c. Catalysts:
1. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
7. 3 clinical programs in 2017 w/ promising human & in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 06/05/2017 – 06/09/2017, and Why?

[Author]

Posts